Grant Number:	5R01CA228198-02 Interpret this number
Primary Investigator:	Huo, Dezheng
Organization:	University Of Chicago
Project Title:	Genetic Risk Prediction of Breast Cancer for African Americans
Fiscal Year:	2019

PROJECT ABSTRACT More than 180 susceptibility loci for breast cancer have been identified by genome-wide association studies (GWAS), mainly in Caucasian populations. However, many of these risk variants cannot be directly replicated in women of African ancestry, suggesting that causal variants are yet to be identified. Polygenic risk scores (PRS), which aggregate common genetic variants identified by GWAS, have been developed to predict genetic risk of breast cancer for Caucasian women, but there is no validated PRS for African American women. The linkage equilibrium in African ancestry populations is much less extensive than in Caucasian and Asian populations, which makes African ancestry population the ideal population to find causative variants after localizing a breast cancer susceptibility locus. Therefore, we propose a comprehensive analytical study that leverages several types of existing genetic datasets for breast cancer available to us and in public domains to address three specific aims. First, we aim to conduct cross-ethnic fine-mapping analysis for narrowing down casual variant candidate lists in 180+ loci of breast cancer. We will compile and harmonize genetic data from studies of breast cancer in women of African ancestry, including 7,525 cases and 6,207 controls, and leverage the association results from Caucasians (>122,000 cases and >105,000 controls), East Asians (>14,000 cases and >13,000 controls), and Latinos (4,400 cases and 7,500 controls). We will use a Bayesian statistical method to directly incorporate multiple functional annotations for the top variants in each locus. Second, we aim to develop breast cancer polygenic risk score models in African Americans by leveraging functional annotations, linkage disequilibrium, and gene expression data. Several PRSs will be developed for overall breast cancer risk and by estrogen receptor, cross-validated internally, and validated with external studies. Third, we aim to develop breast cancer risk prediction model by combining both genetic and non-genetic factors. The proposed study will efficiently utilize several types of existing data using innovative integrative approaches and has the potential to advance the field by narrowing down the genetic regions containing causal variants. More importantly, the risk prediction model has a good potential to translate knowledge from GWAS to the practice of breast cancer screening.